Roivant Sciences Ltd. (ROIV) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Roivant Sciences Ltd. (ROIV)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.96

0.22 (2.05%)

At close: Jan 14, 2025, 3:59 PM

10.72

-2.14%

After-hours Jan 14, 2025, 04:38 PM EST

undefined% (undefined)

Bid	10.61
Market Cap	7.97B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	5.54
PE Ratio (ttm)	1.98
Forward PE	n/a
Analyst	Buy

Ask	11.49
Volume	4,675,366
Avg. Volume (20D)	4,694,301
Open	10.82
Previous Close	10.74
Day's Range	10.81 - 11.25
52-Week Range	9.69 - 13.05
Beta	undefined

About ROIV

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 8, 2020

Employees 908

Stock Exchange NASDAQ

Ticker Symbol ROIV

Website https://roivant.com

Analyst Forecast

According to 8 analyst ratings, the average rating for ROIV stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 64.31% from the latest price.

Buy 87.50%

Hold 12.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Roivant Sciences Ltd. is scheduled to release its earnings on Feb 11, 2025, before market opens.
Analysts project revenue of $5.00M, reflecting a -86.54% YoY shrinking and earnings per share of -0.22, making a 4.76% increase YoY.

Why Price Moved

5 months ago · Source

+6.69%

Roivant Sciences shares are trading higher after t... Unlock content with Pro Subscription

9 months ago · Source

+4.7%

Roivant Sciences shares are trading higher after the company announced results from its NEPTUNE Phase 2 study of brepocitinib. The company's board also authorized a share repurchase program of up to $1.5 billion, including the repurchase of all 71.3 million shares held by Sumitomo Pharma.

News

1 month ago · seekingalpha.com

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT...

1 month ago · reuters.com

Roivant's lung disease drug fails mid-stage trial

Roivant said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of lung disease.

2 months ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimm...

2 months ago · zacks.com

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21.

2 months ago · seekingalpha.com

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant ha...